Developing Biomarker-Supported Schizophrenia Spectrum Disorder (SSD) Prevention

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age9-19
SponsorThe University of Texas Health Science Center, Houston

About this trial

The purpose of this study is to compare the effect of a brief family-based psychosocial intervention that addresses modifiable SSD risk factors on persistent and distressing psychotic-like experiences in children and young adults with a family history of SSD and high versus low baseline SSD-like brain patterns

Eligibility criteria

Qualifiers

Family history of SSD (defined as first-degree (e.g., a parent or a sibling), second-degree (e.g., an uncle or a grandparent), or other combinations of biological relatives in the family have or likely have a diagnosis of SSD or other closely related severe mental illnesses equivalent to at least 25% of genetic sharing) per medical record review and/or parent/legal guardian report and confirmed by a structured interview

screening positive for two or more risk factors targeted by the intervention

Participants and parent(s)/legal guardian(s) agree to participate

psychiatrically stable and have no major changes in antidepressant, stimulant, or antipsychotic medication in the past 4 weeks.

Disqualifiers

Current or past history of psychotic disorders or clinical high risk for psychosis (CHR-p) per study interview

Current or past antipsychotic medication use to specifically treat a psychotic disorder

major medical and neurological conditions

moderate to severe intellectual disabilities or mild intellectual disabilities but expected to have difficulty completing the study assessments;

Trial design

Treatments tested in this trial

  • Psychosocial intervention group

Treatment groups

100 Participants
are divided into 1 treatment group

Sponsors and collaborators

The University of Texas Health Science Center, Houston

Lead sponsor

National Institutes of Health (NIH)

Collaborator